Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement

Pediatric Blood and Cancer

Volumn 50, Issue 4, 2008, Pages 921-923

  Hauer, Julia ^a,f   Tosi, Sabrina ^b   Schuster, Friedhelm R ^a,c   Harbott, Jochen ^d   Kolb, Hans Jochem ^e   Borkhardt, Arndt ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute myeloid leukemia; CD6 depletion; GvL; Haplo HSCT; HLXB9 ETV6 rearrangement; Translocation t(7 ; 12)

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CASE REPORT; CHROMOSOME TRANSLOCATION; DISEASE COURSE; FEMALE; FUSION GENE; GENE REARRANGEMENT; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLXB9 ETV6 FUSION GENE; HLXB9 TEL FUSION GENE; HUMAN; INFANT; LEUKEMIA RELAPSE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 7; FEMALE; GRAFT VS LEUKEMIA EFFECT; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEODOMAIN PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA, MYELOID, ACUTE; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 40449124892     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21376     Document Type: Article

References (9)

1. von Bergh AR, van Drunen E, van Wering ER, et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HL XB9. Genes Chromosomes Cancer 2006;45:731-739.
2. Satake N, Maseki N, Nishiyama M, et al. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 1999;13:1013-1017.
3. Slater RM, von Drunen E, Kroes WG, et al. t(7;12)(q36;p13) and t(7;12)(q32;p13)-translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia 2001;15:915-920.
4. Tosi S, Harbott J, Teigler-Schlegel A, et al. t(7;12)(q36;p13), a new recurrent translocation involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2000;29:325-332.
5. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-1099.
6. Kolb HJ, Guenther W, Gyurkocza B, et al. Tolerance and chimerism. Transplantation 2003;75:26S-31S.
7. Beverloo HB, Panagopoulos I, Isaksson M, et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). Cancer Res 2001;61:5374-5377.
8. Tosi S, Hughes J, Scherer SW, et al. Heterogeneity of the 7q36 breakpoints in the t(7;12) involving ETV6 in infant leukemia. Genes Chromosomes Cancer 2003;38:191-200.
9. Simmons HM, Oseth L, Nguyen P, et al. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia 2002;16:2408-2416.